Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Vical
To compare the safety and efficacy of VL-2397 to standard first-line treatment for invasive aspergillosis in immunocompromised adults with acute leukemia or recipients of an allogeneic hematopoietic cell transplant (allo-HCT).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Acute Leukemia (AML or ALL) patient or allo-HCT recipient with a diagnosis of IA
You may not be if
Pregnant or breastfeeding
IA involving sites other than lungs and sinuses
Graft failure, acute or extensive chronic GvHD
Uncontrolled diabetes
Clareo Health | VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults
